DEXE / USDT

IOST / USDT

RIF / USDT

D / TRY

D / USDT

HYPER / USDT

HYPER / USDC

HYPER / TRY

FUN / USDT

FUN / USDC

GIGGLE / USDT

GIGGLE / USDC

GIGGLE / TRY

币安人生 / USDC

币安人生 / USDT

FIO / USDT

ROBO / USDT

ROBO / TRY

ROBO / USDC

HEMI / USDC

DMCC SPECIALITY CHEMICALS

JINKUSHAL INDUSTRIES LTD

BAWEJA STUDIOS LIMITED

ATLAS CYCLE (HARYANA) LTD

PARSVNATH DEVELOPER LTD

NATH BIO-GENES (I) LTD

MAHINDRA EPC IRRIG LTD

ENVIRO INFRA ENGINEERS L

BIRLA CABLE LIMITED

INDIABULLS LIMITED

JYOTI CNC AUTOMATION LTD

SYLVAN PLYBOARD (INDIA) L

EPPELTONE ENGINEERS LTD

SUNREST LIFESCIENCE LTD

PRAXIS HOME RETAIL LTD

SUNGARNER ENERGIES LTD

SAMEERA AGRO AND INFRA L

MARVEL DECOR LIMITED

EXXARO TILES LIMITED

ENCOMPASS DESIGN INDIA L

Click here to get full coverage on Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout - Investor's Business Daily

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout  Investor's Business Daily

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout - Investor's Business Daily

Click here to get full coverage on FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan

FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor  Stock Titan

FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan

Click here to get full coverage on Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga

Why Is Praxis Precision Stock Soaring Tuesday?  Benzinga

Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga

Click here to get full coverage on FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com

FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor  Investing.com

FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com

Click here to get full coverage on Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha

Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ)  Seeking Alpha

Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027 - Quiver Quantitative

Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027  Quiver Quantitative

Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027 - Quiver Quantitative

Click here to get full coverage on Praxis Precision Medicines Announces FDA Acceptance of New - GlobeNewswire

Praxis Precision Medicines Announces FDA Acceptance of New  GlobeNewswire

Praxis Precision Medicines Announces FDA Acceptance of New - GlobeNewswire

Click here to get full coverage on Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks

Praxis Precision NDA for Ulixacaltamide in Essential Tremor  TipRanks

Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks

Click here to get full coverage on Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - Investing News Network

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026  Investing News Network

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - Investing News Network

Click here to get full coverage on Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors? - simplywall.st

Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?  simplywall.st

Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors? - simplywall.st

Click here to get full coverage on Subhas Chandra Bose: Philosophy, Politics, and Praxis - Part 2 - The Hindu

Subhas Chandra Bose: Philosophy, Politics, and Praxis - Part 2  The Hindu

Subhas Chandra Bose: Philosophy, Politics, and Praxis - Part 2 - The Hindu

Click here to get full coverage on Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - National Today

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026  National Today

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - National Today

Click here to get full coverage on FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan

FDA starts Praxis review for essential tremor drug, decision due Jan. 2027  Stock Titan

FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan

Click here to get full coverage on Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com

Praxis Precision Medicines stock rating reiterated at Buy by BTIG  Investing.com

Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com

Click here to get full coverage on Why Praxis Precision Medicines Shares Are Sinking Today - TipRanks

Why Praxis Precision Medicines Shares Are Sinking Today  TipRanks

Why Praxis Precision Medicines Shares Are Sinking Today - TipRanks

Click here to get full coverage on Jefferies reiterates Praxis Precision Medicines stock rating on FDA review - Investing.com

Jefferies reiterates Praxis Precision Medicines stock rating on FDA review  Investing.com

Jefferies reiterates Praxis Precision Medicines stock rating on FDA review - Investing.com

Click here to get full coverage on FDA accepts Praxis application for essential tremor treatment - Investing.com

FDA accepts Praxis application for essential tremor treatment  Investing.com

FDA accepts Praxis application for essential tremor treatment - Investing.com

Click here to get full coverage on Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance By Investing.com - Investing.com South Africa

Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance By Investing.com  Investing.com South Africa

Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance By Investing.com - Investing.com South Africa

Click here to get full coverage on Praxis to present essential tremor drug data at neurology meeting - Investing.com

Praxis to present essential tremor drug data at neurology meeting  Investing.com

Praxis to present essential tremor drug data at neurology meeting - Investing.com

Click here to get full coverage on Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy - Investing.com

Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy  Investing.com

Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy - Investing.com

Click here to get full coverage on What is to Be Done? Toward a Praxis of Resistance - CounterPunch.org

What is to Be Done? Toward a Praxis of Resistance  CounterPunch.org

What is to Be Done? Toward a Praxis of Resistance - CounterPunch.org

Click here to get full coverage on Praxis Precision Medicines stock (US74006W1036): Does its CNS pipeline now hold the key to biotech u - AD HOC NEWS

Praxis Precision Medicines stock (US74006W1036): Does its CNS pipeline now hold the key to biotech u  AD HOC NEWS

Praxis Precision Medicines stock (US74006W1036): Does its CNS pipeline now hold the key to biotech u - AD HOC NEWS

Click here to get full coverage on Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX) - Seeking Alpha

Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX)  Seeking Alpha

Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX) - Seeking Alpha

Click here to get full coverage on A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance

A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine  Yahoo Finance

A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance

Click here to get full coverage on Biopharma bites: Apnimed stocks up for sleep apnoea launch, plus Praxis' seizure success - FirstWord Pharma

Biopharma bites: Apnimed stocks up for sleep apnoea launch, plus Praxis' seizure success  FirstWord Pharma

Biopharma bites: Apnimed stocks up for sleep apnoea launch, plus Praxis' seizure success - FirstWord Pharma

Click here to get full coverage on Subhas Chandra Bose: the paradox of a revolutionary’s theory and praxis - The Hindu

Subhas Chandra Bose: the paradox of a revolutionary’s theory and praxis  The Hindu

Subhas Chandra Bose: the paradox of a revolutionary’s theory and praxis - The Hindu

Click here to get full coverage on 18 new Praxis hires receive stock awards that vest over 4 years - Stock Titan

18 new Praxis hires receive stock awards that vest over 4 years  Stock Titan

18 new Praxis hires receive stock awards that vest over 4 years - Stock Titan

Click here to get full coverage on Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial - Endpoints News

Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial  Endpoints News

Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial - Endpoints News

Click here to get full coverage on Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Click here to get full coverage on FDA fast-tracks Praxis drug for rare childhood epilepsy disorders - Stock Titan

FDA fast-tracks Praxis drug for rare childhood epilepsy disorders  Stock Titan

FDA fast-tracks Praxis drug for rare childhood epilepsy disorders - Stock Titan

Click here to get full coverage on Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine - Stock Titan

Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine  Stock Titan

Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine - Stock Titan

Click here to get full coverage on Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewswire

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy  GlobeNewswire

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewswire

Click here to get full coverage on In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan

In a nine-patient Praxis trial, children had 77% fewer seizures  Stock Titan

In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan

Click here to get full coverage on Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported - Stock Titan

Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported  Stock Titan

Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported - Stock Titan

Click here to get full coverage on Praxis Precision Medicines Announces FDA Acceptance and - GlobeNewswire

Praxis Precision Medicines Announces FDA Acceptance and  GlobeNewswire

Praxis Precision Medicines Announces FDA Acceptance and - GlobeNewswire

Click here to get full coverage on PRAXIS, INC: 2026 - NYU Tisch School of the Arts

PRAXIS, INC: 2026  NYU Tisch School of the Arts

PRAXIS, INC: 2026 - NYU Tisch School of the Arts

Click here to get full coverage on Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies - NeurologyLive

Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies  NeurologyLive

Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies - NeurologyLive

Click here to get full coverage on EDGE 2026, Startup Clinic & Pitch Competition at Praxis Business School to Unite Academia and Industry - Telegraph India

EDGE 2026, Startup Clinic & Pitch Competition at Praxis Business School to Unite Academia and Industry  Telegraph India

EDGE 2026, Startup Clinic & Pitch Competition at Praxis Business School to Unite Academia and Industry - Telegraph India

Click here to get full coverage on Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue - Yahoo Finance

Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue  Yahoo Finance

Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue - Yahoo Finance

Click here to get full coverage on New Latitude Praxis Whitetail Frame Pack for Mobile Hunters - Bowhunter

New Latitude Praxis Whitetail Frame Pack for Mobile Hunters  Bowhunter

New Latitude Praxis Whitetail Frame Pack for Mobile Hunters - Bowhunter

Click here to get full coverage on Study.com Announces First-to-Market PRAXIS® 8000 Series and Flexible Path Test Prep in Collaboration with ETS - 24-7 Press Release Newswire

Study.com Announces First-to-Market PRAXIS® 8000 Series and Flexible Path Test Prep in Collaboration with ETS  24-7 Press Release Newswire

Study.com Announces First-to-Market PRAXIS® 8000 Series and Flexible Path Test Prep in Collaboration with ETS - 24-7 Press Release Newswire

Click here to get full coverage on Rapides School Board OKs help for teachers trying to pass test - The Town Talk

Rapides School Board OKs help for teachers trying to pass test  The Town Talk

Rapides School Board OKs help for teachers trying to pass test - The Town Talk

Click here to get full coverage on SEQSTER and Praxis expand collaboration to expedite CNS disorder trials - Clinical Trials Arena

SEQSTER and Praxis expand collaboration to expedite CNS disorder trials  Clinical Trials Arena

SEQSTER and Praxis expand collaboration to expedite CNS disorder trials - Clinical Trials Arena

Click here to get full coverage on Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) - Yahoo Finance

Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)  Yahoo Finance

Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) - Yahoo Finance

Click here to get full coverage on James Park's "Paradox of Praxis" Video - Thrasher Magazine

James Park's "Paradox of Praxis" Video  Thrasher Magazine

James Park's "Paradox of Praxis" Video - Thrasher Magazine

Click here to get full coverage on Praxis Precision Medicines Q4 Earnings Call Highlights - Yahoo Finance

Praxis Precision Medicines Q4 Earnings Call Highlights  Yahoo Finance

Praxis Precision Medicines Q4 Earnings Call Highlights - Yahoo Finance

Click here to get full coverage on Mintz Advises on Praxis Precision Medicines’ $661 Million Public Offering - Mintz

Mintz Advises on Praxis Precision Medicines’ $661 Million Public Offering  Mintz

Mintz Advises on Praxis Precision Medicines’ $661 Million Public Offering - Mintz

Click here to get full coverage on How Investors Are Reacting To Praxis (PRAX) Advancing Breakthrough NDA Plans With a 2028 Cash Runway - Yahoo Finance

How Investors Are Reacting To Praxis (PRAX) Advancing Breakthrough NDA Plans With a 2028 Cash Runway  Yahoo Finance

How Investors Are Reacting To Praxis (PRAX) Advancing Breakthrough NDA Plans With a 2028 Cash Runway - Yahoo Finance

Click here to get full coverage on SEQSTER, Praxis Extend Partnership - Contract Pharma

SEQSTER, Praxis Extend Partnership  Contract Pharma

SEQSTER, Praxis Extend Partnership - Contract Pharma

Click here to get full coverage on Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway - Yahoo Finance

Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway  Yahoo Finance

Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway - Yahoo Finance

Click here to get full coverage on Praxis NDAs And FDA Designations Put Focus On Valuation Upside - Yahoo Finance

Praxis NDAs And FDA Designations Put Focus On Valuation Upside  Yahoo Finance

Praxis NDAs And FDA Designations Put Focus On Valuation Upside - Yahoo Finance

Click here to get full coverage on Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA - Fierce Biotech

Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA  Fierce Biotech

Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA - Fierce Biotech

Click here to get full coverage on Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - The Motley Fool

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline  The Motley Fool

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline - The Motley Fool

Click here to get full coverage on Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? - Yahoo Finance

Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run?  Yahoo Finance

PRAXIS

Price Chart

Key Statistics

Technicals

About PRAXIS

Latest News

Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout - Investor's Business Daily

FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan

Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga

Advanced Charts

Top Gainers

Top Losers